The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
WT1 rs16754 polymorphism correlated with favorable outcomes in AML
Wilms’ Tumor-1 (WT1) single nucleotide polymorphism (SNP), SNP rs16754, has been reported that it is an independent prognostic factor for Acute Myeloid Leukemia (AML) patients. However, its role in the clinical outcomes of AML patients is still debatable.
Jessica Petiti from the University of Turin, Turin, Italy, et al. analyzed the association between SNP rs16754 and Overall Survival (OS) or Event Free Survival (EFS) of patients with AML. The data were published ahead of print in Leukemia Research on 29 January 2018.
Using a sensitive tool, peptide nucleic acid (PNA) directed polymerase chain reaction (PCR) Clamping technology, to identify polymorphisms, the authors analyzed bone marrow (BM) or peripheral blood (PB) mononuclear cells from 87 AML patients.
Key findings:
- WT1 rs16754 polymorphism (rs16754 GA/GG) was found in 32.2% (28/87) of all cases
- Median OS in patients with rs16754 GA/GG (n = 28) and rs16754 AA (n = 59) genotype: 84 vs 9 months, P < 0.0001
- Median EFS in patients with rs16754 GA/GG and rs16754 AA genotype: 23 vs 3 months, P < 0.0001
- Compared to WT1 rs16754 AA, median OS was significantly better in WT rs16754 GA/GG patients treated with chemotherapy (P = 0.0007) and demethlyating therapy (P = 0.0095)
- WT1 rs16754 GA/GG expression at diagnosis was an independent predictor of EFS (HR = 0.2, P < 0.0001) and OS (HR = 0.087), P < 0.0001
The study group concluded by stating that WT1 rs16754 GA/GG genotype correlated with favorable outcomes in adult patients with AML. Even though these data require further validations, the authors suggested that WT1 rs16754 GA/GG could be used as an independent prognostic factor for risk-stratification in AML.
References